EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE

This article presents the results of the comparative antitumor efficacy study of two test articles of therapeutic humanized monoclonal antibodies against epidermal growth factor receptor (EGFR) manufactured by Russian biopharmaceutical company CJSC “Biocad” and the commercial drug “Erbitux®” (Merck,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ya. Yu. Ustyugov, A. A. Aleksandrov, M. V. Artyukova, M. A. Varavko
Formatua: Artigo
Hizkuntza:Russo
Argitaratua: Tomsk National Research Medical Center of the Russian Academy of Sciences 2016-02-01
Saila:Sibirskij Onkologičeskij Žurnal
Gaiak:
a431ns, erbitux®, xenograft, immunodeficient mice, tumor growth inhibition, antitumor efficacy, human epidermoid carcinoma, tumor growth index
Sarrera elektronikoa:https://www.siboncoj.ru/jour/article/view/222
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak